A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That Has Progressed During or Following Docetaxel-based Therapy
收藏DataCite Commons2026-03-11 更新2024-07-13 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00001500/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
This is a randomized, double-blind, multicenter, phase 3 study evaluating orteronel plus prednisone compared with placebo plus prednisone in men with metastatic, castration-resistant prostate cancer (mCRPC) that has progressed following Docetaxel-based therapy
提供机构：
Vivli
创建时间：
2018-10-27
